Research Article
Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation
Table 1
Characteristics of recipients, tumors, and donors.
| | Number of subjects | 82 |
| | Characteristics of recipients | |
| | Age at LT [years] | 57.2 ± 9.4 | | Males | 68 (82.9 %) | | Body Mass Index [kg/m2] | 27.56 ± 5.07 |
| | Primary liver disease |
| | Alcoholic cirrhosis | 21 (25.6 %) | | Autoimmune hepatitis | 2 (2.4 %) | | Hepatitis B | 21 (25.6%) | | Hepatitis C | 21 (25.6 %) | | Non-alcoholic fatty liver disease | 3 (3.7 %) | | Hemochromatosis | 2 (2.4 %) | | Cryptogenic cirrhosis | 8 (9.8 %) | | Secondary sclerosing cholangitis | 1 (1.2 %) | | Alpha-1-deficiency | 1 (1.2 %) | | Drug-induced liver injury | 2 (2.4 %) |
| | Fibrosis (according to Batts and Ludwig score) |
| | none | 5 (6.1%) | | grade 3 | 4 (4.9%) | | grade 4 | 73 (89.0 %) |
| | Time from HCC diagnosis to LT [months] | 7 (IQR 2-12) |
| | Immunosuppression |
| | Ciclosporin | 10 (12.2 %) | | Tacrolimus | 56 (68.3%) | | Everolimus | 23 (28.0 %) | | Sirolimus | 14 (17.1 %) | | Mycophenolate Mofetil | 62 (75.6 %) |
| | Survival after LT [months] (all patients) | 49.50 (IQR 24.50-84.75) |
| | male patients | 42.00 (IQR 23.50-91.50) | | female patients | 59.50 (IQR 27.50-74.25) |
| | Death | 36 (43,9 %) |
| | Recurrence | 28 (34.1 %) |
| | Recurrence-free survival [months] | 12.50 (IQR 6-28.25) |
| | Therapy for HCC (bridging/downstaging) before LT |
| | No therapy | 17 (20.7%) | | TACE | 45 (54.9 %) | | SIRT/radiation | 8 (9.8%) | | Resection | 16 (19.5%) | | Radiofrequency ablation | 8 (9.8%) |
| | Remission | |
| | partial | 43 (52.4 %) | | complete | 16 (19.5 %) |
| | Targeted biopsy before LT | 52 (65.0 %) |
| | Tumor characteristics | |
| | AFP pre-LT [ng/ml] | 13850 (IQR 5350-135975) | | Milan Criteria fulfilled | 38 (46.3 %) | | Number of HCC lesions: | | 1 | 32 (39.0 %) | | 2-3 | 25 (30.5 %) | | > 3 | 9 (11.0 %) | | Disseminated tumor infiltration | 16 (19.5 %) | | Maximum size of HCC lesion(s) [cm] | | < 3 | 30 (36.6 %) | | 3-5 | 25 (30.5 %) | | >5 | 26 (31.7 %) | | Microvascular invasion | 21 (25.6 %) | | Lymphatic invasion | 5 (6.1 %) | | Tumor Grading | | Complete remission and no biopsy prior to LT | 6 (7.3 %) | | grade 1 | 12 (14.6 %) | | grade 2 | 53 (64.6 %) | | grade 3 | 9 (11.0 %) | | grade 4 | 2 (2.4 %) |
| | Donor Characteristics |
| | Age [years] | 50.9 ± 15.4 | | Male sex | 52 (63.4 %) | | Body Mass Index [kg/m2] | 26.47 ± 4.33 |
|
|
More than one option is possible per patient. Data are presented as mean and standard deviation or median and interquartile range as appropriate. |
